4.4 Article

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1-Full Report

Journal

JOURNAL OF CLINICAL LIPIDOLOGY
Volume 9, Issue 2, Pages 129-169

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacl.2015.02.003

Keywords

Clinical recommendations; Dyslipidemia; Atherogenic cholesterol; Low-density lipoprotein cholesterol; Lipoproteins; Atherosclerotic cardiovascular disease; Coronary heart disease

Funding

  1. Merck and Co
  2. Amarin
  3. AstraZeneca
  4. Regeneron/Sanofi-Aventis
  5. Kowa Pharmaceuticals
  6. Abbvie
  7. Matinas BioPharma
  8. Pharmavite
  9. Sancilio
  10. Trygg Pharmaceuticals
  11. Ardea
  12. Amgen
  13. Arisaph
  14. California Raisin Marketing Board
  15. Catabasis
  16. Cymabay
  17. Eisai
  18. Elcelyx
  19. Eli Lilly
  20. Esperion
  21. Gilead
  22. Hanmi
  23. Hisun
  24. Hoffman-La Roche
  25. Home Access
  26. Janssen
  27. Johnson and Johnson
  28. Merck
  29. Necktar
  30. Novartis
  31. Novo Nordisk
  32. Omthera
  33. Orexigen
  34. Pfizer
  35. Pronova
  36. Regeneron
  37. Sanofi
  38. Takeda
  39. TIMI
  40. VIVUS Inc
  41. Wpu Pharmaceuticals
  42. Lily
  43. Philips Medical Systems
  44. Merck Sharpe Dohme
  45. Novo Nordisk Inc.
  46. Bristol-Myers Squibb
  47. Genzyme
  48. Pfizer, Inc,
  49. LipoScience, Inc
  50. GlaxoSmithKline
  51. Medtelligence
  52. Vindico

Ask authors/readers for more resources

The leadership of the National Lipid Association convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. An Executive Summary of those recommendations was previously published. This document provides support for the recommendations outlined in the Executive Summary. The major conclusions include (1) an elevated level of cholesterol carried by circulating apolipoprotein B-containing lipoproteins (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol [LDL-C], termed atherogenic cholesterol) is a root cause of atherosclerosis, the key underlying process contributing to most clinical atherosclerotic cardiovascular disease (ASCVD) events; (2) reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the extent that atherogenic cholesterol is reduced. This benefit is presumed to result from atherogenic cholesterol lowering through multiple modalities, including lifestyle and drug therapies; (3) the intensity of risk-reduction therapy should generally be adjusted to the patient's absolute risk for an ASCVD event; (4) atherosclerosis is a process that often begins early in life and progresses for decades before resulting a clinical ASCVD event. Therefore, both intermediate-term and long-term or lifetime risk should be considered when assessing the potential benefits and hazards of risk-reduction therapies; (5) for patients in whom lipid-lowering drug therapy is indicated, statin treatment is the primary modality for reducing ASCVD risk; (6) nonlipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure, cigarette smoking, and diabetes mellitus; and (7) the measurement and monitoring of atherogenic cholesterol levels remain an important part of a comprehensive ASCVD prevention strategy. (C) 2015 National Lipid Association. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available